Weight Loss Pens: Anvisa Investigates Cases of Vision Loss
4 Articles
4 Articles
Anvisa investigates 13 reports of suspected non-arteritic anterior ischemic optic neuropathy (Noia), a rare lesion in the optic nerve that can cause permanent loss of vision, in patients who used GLP-1 agonists class drugs, indicated for diabetes and obesity. The disease functions as a nerve infarction that binds the eye to the brain. Small vessels that irrigate it clog, part of the nerve cells dies and the vision of one of the eyes suddenly wor…
Agency assesses 13 notifications of rare injury to optic nerve
Patients using GLP-1 agonists class drugs report a rare lesion that clogs vessels of the optic nerve. Read on Power360.
The National Agency for Health Surveillance (Anvisa) investigates 13 reports of suspected non-arteritic anterior ischemic optic neuropathy (Noia) in patients who used GLP-1 agonists class drugs, indicated for the treatment of diabetes and obesity.The records involve users of Ozempic, Wegovy, Rybelsus and Moungharo. The agency, however, emphasizes that the existence of a notification in which the patient used one of these drugs and presented the …
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
